Adis Journals
Vonoprazan Adis Drug Evaluation Summary slide -UPDATED.pdf (240.95 kB)

Vonoprazan: A Review in Helicobacter pylori Infection

Download (240.95 kB)
online resource
posted on 2024-02-11, 21:57 authored by Matt Shirley


Acknowledgments  During the peer review process the manufacturer of Voquezna® Triple Pak and Voquezna® Dual Pak was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Matt Shirley is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here.
Treatment for the eradication of Helicobacter pylori infection, a leading cause of peptic ulcer disease and an important risk factor for gastric cancer and mucosa-associated lymphoid tissue lymphoma, is indicated whenever infection is identified. However, treatment success rates with current guideline-recommended proton-pump inhibitor (PPI)-based regimens remain suboptimal, with one potential factor associated with treatment failure being inadequate acid suppression. Vonoprazan (Voquezna®) is a first-in-class potassium-competitive acid blocker with the potential to provide potent and sustained acid suppression. Following clinical trials conducted mainly in Asia (supported by post-marketing experience from Asia) and the phase III PHALCON-HP trial conducted in the USA and Europe, vonoprazan is now approved in the USA for use in combination with amoxicillin (dual therapy) or amoxicillin and clarithromycin (triple therapy) for the treatment of H. pylori infection in adults. The vonoprazan-based dual and triple therapy regimens were generally well tolerated in PHALCON-HP. In addition, vonoprazan has advantages including a rapid onset of action and no food effect, making vonoprazan-based dual and triple therapy regimens valuable alternatives to standard PPI-based triple therapy in the treatment of H. pylori infection.

© Springer Nature Switzerland AG 2024 


Usage metrics





    Ref. manager